Author: Willem van Lawick

Ghent, Belgium, 20th January 2012 – Pronota NV today announced the close of a Series C financing, raising EUR 3.7 million from existing investors; LSP, Gimv, Biotech Fund Flanders, KBC Private Equity, Johnson & Johnson Development Corporation, VIB, MP Healthcare and MedSciences Capital, and a company founder. (more…)

Leiden, The Netherlands, 1 December 2011 – Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics for rare diseases with unmet medical needs, announced today that it has received financing of $1.5m for three years from the charitable organisation Charley’s Fund, to support development of compounds for the skipping of exon 52 in patients with Duchenne Muscular Dystrophy (DMD). (more…)

Leiden, The Netherlands, 17 November 2011 – Prosensa, the Dutch company focusing on RNA modulating therapeutics for rare diseases with unmet medical needs, has been granted two new patents for exon-skipping by the Japanese Patent Office and the United States Patent and Trademark Office, and has confirmed its strong position in Europe during an opposition procedure which was concluded yesterday. (more…)

Groningen, the Netherlands, November 15, 2011 / B3C newswire / – Dutch biotechnology company Mucosis B.V. today announced that it has appointed professors Jiri Mestecky, M.D., Ph.D.; Willem van Eden, M.D., Ph.D.; and Peter J. Openshaw, M.B., B.S., Ph.D., F.Med.Sci., to its newly formed Scientific Advisory Board. (more…)

Leiden, The Netherlands, 8 November 2011 – Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, has won EuropaBio’s Most Innovative European Biotech SME Award 2011, presented at a ceremony in Brussels earlier today. The award comes with prize money of €10,000 and two years’ membership of EuropaBio. (more…)